Commercializing Angiogenesis Affecting Drugs in Cancer: The ...

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

NEW YORK, Feb. 6, 2012 ? (PRNewswire) ? ??Reportlinker.com announces that a new market research report is available in its catalogue: Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0769058/Commercializing-Angiogenesis-Affecting-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report: * The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.1 Executive Summary 32 About Cancer Highlights? 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'? Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 224.2 List of Tables225 Introduction 375.1 The Scope of this Report 375.2 Definitions 405.3 Abbreviations 406 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 416.1 Drug Repositioning in Oncology 416.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology 426.2.1 Calcium Ion Binding Targets 486.2.2 Carboxy-lyase Activity Targets 496.2.3 Catalytic Activity Targets 516.2.4 Cell Adhesion Molecule Activity Targets 566.2.5 Chaperone Activity Targets 636.2.6 Chemokine Activity Targets 676.2.7 Cofactor Binding Targets 696.2.8 Cysteine-type Peptidase Activity Targets 716.2.9 Cytokine Activity Targets 766.2.10 Cytoskeletal Protein Binding Targets 806.2.11 DNA Topoisomerase Activity Targets 816.2.12 DNA-directed DNA Polymerase Activity Targets 846.2.13 Extracellular Matrix Structural Constituent Targets 856.2.14 G-protein Coupled Receptor Activity Targets 916.2.15 Growth Factor Activity Targets 966.2.16 GTPase Activity Targets 1126.2.17 Hormone Activity Targets 1156.2.18 Hydrolase Activity Targets 1166.2.19 Kinase Activity Targets 1186.2.20 Kinase Binding Targets 1216.2.21 Lipid Kinase Activity Targets 1236.2.22 Metallopeptidase Activity Targets 1306.2.23 Molecular Function Unknown Targets 1486.2.24 Motor Activity Targets 1496.2.25 Oxidoreductase Activity Targets 1516.2.26 Peptidase Activity Targets 1536.2.27 Phosphoric Diester Hydrolase Activity Targets 1696.2.28 Protease Inhibitor Activity Targets 1726.2.29 Protein Binding Targets 1766.2.30 Protein Serine/Threonine Kinase Activity Targets 1806.2.31 Protein-tyrosine Kinase Activity Targets 2096.2.32 Receptor Activity Targets 2206.2.33 Receptor Binding Targets 2456.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 2516.2.35 RNA Binding Targets 2536.2.36 Serine-type Peptidase Activity Targets 2546.2.37 Structural Constituent of Cytoskeleton Targets 2596.2.38 Superoxide Dismutase Activity Targets 2616.2.39 Transcription Factor Activity Targets 2646.2.40 Transcription Regulator Activity Targets 2776.2.41 Transferase Activity Targets 2846.2.42 Translation Regulator Activity Targets 2866.2.43 Transmembrane Receptor Activity Targets 2936.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 2956.2.45 Transporter Activity Targets 3486.2.46 Ubiquitin-specific Protease Activity Targets 3526.2.47 Unknown Function Targets 3536.2.48 Voltage-gated Ion Channel Activity Targets 3546.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology 3556.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3556.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets 3606.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 3646.6 The Drug-Target Competitive Landscape 3686.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology 3726.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology 3756.8.1 Tools for Analysis of Cancer Pathways 3766.8.2 Pathway Assessment 3777 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development 4247.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4317.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4387.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4467.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology 4507.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology 4547.7.1 Marketed 4587.7.2 Pre-registration 4737.7.3 Phase III 4777.7.4 Phase II 5157.7.5 Phase I 5517.7.6 Preclinical 5827.7.7 Suspended 6187.7.8 Ceased 6197.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology 6608 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy 6678.1 Small Molecules 6698.1.1 Background 6698.1.2 Target Strategies of Small Molecule Drugs 6708.2 Peptide & Protein Drugs 6828.2.1 Background 6828.2.2 Target Strategies of Peptide and Protein Drugs 6838.3 Antibodies 6898.3.1 Background 6898.3.2 Target Strategies of Antibody Drugs 6898.4 Nucleic Acid Therapies 6948.4.1 Background 6948.4.2 Target Strategies of Nucleic Acid Drugs 6958.5 Gene Therapy 6978.5.1 Background 6978.5.2 Target Strategies of Gene Therapy Drugs 6978.6 Drug Delivery and Nanotechnology 7008.6.1 Background 7008.6.2 Target Strategies of Reformulated Drugs 7008.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 7039 Selecting Indication for Angiogenesis Affecting Drugs in Oncology 7109.1 Acute Lymphocytic Leukemia 7139.2 Acute Myelogenous Leukemia 7149.3 Adrenal Cancer 7179.4 B-cell Lymphoma 7189.5 Basal Cell Cancer 7199.6 Biliary Cancer 7209.7 Bladder Cancer 7219.8 Bone Cancer 7249.9 Brain Cancer 7259.10 Breast Cancer 7289.11 Cancer (general) 7349.12 Carcinoid 7359.13 Cervical Cancer 7379.14 Chemopreventative 7389.15 Chronic Lymphocytic Leukemia 7399.16 Chronic Myelogenous Leukemia 7409.17 Chronic Myelomonocytic Leukemia 7419.18 CNS Cancer 7419.19 Colorectal Cancer 7429.20 Endometrial Cancer 7489.21 Fallopian Tube Cancer 7509.22 Fibro Sarcoma 7529.23 Gastrointestinal Cancer (general) 7539.24 Gastrointestinal Stomach Cancer 7569.25 Gastrointestinal Stromal Cancer 7599.26 Head and Neck Cancer 7619.27 Hematological Cancer (general) 7649.28 Hodgkin's Lymphoma 7659.29 Kaposi's Sarcoma 7669.30 Leiomyo Sarcoma 7679.31 Leukemia (general) 7689.32 Lipo Sarcoma 7699.33 Liver Cancer 7709.34 Lung Cancer (general) 7749.35 Lymphangioleiomyomatosis 7769.36 Lymphoma (general) 7779.37 Mast Cell Leukemia 7799.38 Mastocytosis 7799.39 Melanoma 7809.40 Mesothelioma 7849.41 Myelodysplastic Syndrome 7879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44 CDG Therapeutics 108510.45 Celecure 108910.46 Celera 109310.47 Celgene 109710.48 Cell Therapeutics 110510.49 CellCeutix 111010.50 Cellmid 111410.51 Cephalon 111810.52 ChemoCentryx 112210.53 Chemokine Therapeutics 112610.54 China Sky One Medical 113010.55 Choongwae 113410.56 Circadian Technologies 113910.57 Cue Biotech 114410.58 Curis 114810.59 Cyclacel 115410.60 Cytochroma 115810.61 Deciphera Pharmaceuticals 116210.62 Dendreon 116610.63 Dyax 117010.64 Eisai 117410.65 Eli Lilly 118110.66 EntreMed 119510.67 Exelixis 120610.68 ExonHit Therapeutics 121810.69 Five Prime Therapeutics 122210.70 GammaCan 122610.71 Genmab 123310.72 Gilead Sciences 124010.73 GlaxoSmithKline 124710.74 GlycoGenesys 125410.75 Green Cross 125910.76 Hoffmann-La Roche 126410.77 Hy BioPharma 127610.78 Idera Pharmaceuticals 128010.79 ImClone Systems 128710.80 ImmunoGen 129210.81 ImmuPharma 129610.82 Introgen Therapeutics 130010.83 Isis Pharmaceuticals 130510.84 Johnson & Johnson 130910.85 KAI Pharmaceuticals 131710.86 Karus Therapeutics 132210.87 Kirin Pharma 132610.88 Kringle Pharma 133010.89 Kyowa Hakko Kirin 133410.90 Lee's Pharmaceutical 134010.91 Lorus Therapeutics 134410.92 MAT Biopharma 134810.93 MediGene 135210.94 Merck & Co 135810.95 Merck KGaA 136210.96 Mersana Therapeutics 136910.97 MethylGene 137310.98 Micromet 137710.99 MolMed 138110.100 Morvus Technology 138610.101 NewSouth Innovations 139010.102 Non-industrial Source 139410.103 Novartis 139810.104 Novelix 141710.105 Noxxon 142110.106 Oasmia 142510.107 Onconova 142910.108 OncoTherapy Science 143510.109 Oncothyreon 144110.110 OSI Pharmaceuticals 144610.111 Oxford BioMedica 145110.112 OXiGENE 145510.113 Pepscan Therapeutics 146110.114 PepTx 146810.115 Peregrine Pharmaceuticals 147210.116 Pfizer 147910.117 Pharmacopeia 149910.118 PharmaMar 150410.119 Pharminox 151010.120 Philogen 151410.121 PhiloGene 151810.122 Pierre Fabre 152210.123 Progen 152810.124 Protein Sciences 153210.125 Protgen 153710.126 PTC Therapeutics 154210.127 Receptor BioLogix 154910.128 Regeneron 155310.129 Rexahn 156110.130 Rigel 156510.131 Sanofi 156910.132 Santaris Pharma 157610.133 Scancell 158210.134 SciClone Pharmaceuticals 158610.135 Semafore Pharmaceuticals 159010.136 Shionogi 159610.137 Simcere Pharmaceuticals 160010.138 Spear Therapeutics 160810.139 SRI International 161210.140 Stainwei Biotech 161810.141 SuperGen 162210.142 Switch Pharma 162610.143 SynDevRx 163010.144 Taiho 163410.145 Tau Therapeutics 163810.146 ThromboGenics 164210.147 Tigris Pharmaceuticals 164610.148 ToolGen 165010.149 TopoTarget 165710.150 Tracon Pharmaceuticals 166110.151 UCB 166510.152 VBL Therapeutics 167210.153 Wilex 167610.154 Xerion 168211 Disclaimer 168612 Drug Index 168713 Company Index 1697

---

?Be the first to review this article

Source: http://www10.nanotechcafe.com/nbc/articles/view_article.php?articleid=1056554

stand and deliver when does ios 5 come out when does ios 5 come out christopher columbus trina the green mile the green mile